Pancreatic cancer drug shows tumor shrinkage in early trial results
A drug called daraxonrasib combined with chemotherapy caused substantial tumor shrinkage in patients with pancreatic cancer that had spread to other parts of the body, according to results from a Phase I/II clinical trial presented at a cancer research conference in Barcelona, Spain.
The trial tested the combination in patients who had not previously received treatment for metastatic disease (cancer that has spread). A doctor at Memorial Sloan Kettering Cancer Center said the results were encouraging because the treatment not only shrank tumors but also helped control the disease for longer periods.
Pancreatic cancer is difficult to treat, especially when it has already spread. According to the trial information, most patients with metastatic pancreatic cancer treated with standard chemotherapy alone survive between eight and 11 months, and only 3% are alive five years after diagnosis. Tumor shrinkage occurs in only 23% to 42% of patients on chemotherapy, and most tumors begin growing again after five to six months.
The trial results suggest the new combination may help more patients see tumor shrinkage and maintain disease control longer than chemotherapy alone, though the research is still in early stages.
What it means in Raleigh
Behavioral health: Alliance Health (LME/MCO for Wake, Durham, Johnston, Orange, Cumberland, Mecklenburg)
Medicaid plans: NC Medicaid Standard Plans: AmeriHealth Caritas NC, Carolina Complete Health, Healthy Blue, UnitedHealthcare Community Plan, WellCare of NC. Tailored Plans: Alliance Health, Trillium Health Resources, Vaya Partners (Vaya Health + Partners Health Management, merged 2026).
Major insurers: Blue Cross NC, Aetna, Cigna, UnitedHealthcare, Humana
Plan lists change; confirm with your plan or the state agency.
